Cost-effectiveness of benralizumab in patients with uncontrolled severe eosinophilic asthma in Spain
M. Mareque (Madrid, Spain), M. Climente (Valencia, Spain), E. Martínez-Moragon (Valencia, Spain), A. Padilla (Málaga, Spain), I. Oyagüez (Madrid, Spain), C. Touron (Madrid, Spain), C. Torres (Madrid, Spain)
Source: International Congress 2022 – Studies targeting IL-5 pathways in asthma
Session: Studies targeting IL-5 pathways in asthma
Session type: Thematic Poster
Number: 2137
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Mareque (Madrid, Spain), M. Climente (Valencia, Spain), E. Martínez-Moragon (Valencia, Spain), A. Padilla (Málaga, Spain), I. Oyagüez (Madrid, Spain), C. Touron (Madrid, Spain), C. Torres (Madrid, Spain). Cost-effectiveness of benralizumab in patients with uncontrolled severe eosinophilic asthma in Spain. 2137
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|